NCT07062406Recruiting
Enhancing Diabetes Care by Treating Insomnia
Enhancing Diabetes Care: Implementing Cognitive Behavioral Therapy for Insomnia to Improve Sleep and Cardiometabolic Outcomes
Source: ClinicalTrials.gov · Last updated 2 Sept 2026
Brief summary (registry, in English)
Insomnia is highly prevalent in individuals with type 2 diabetes (T2D) and is associated with poor glycemic control. Louisiana has one of the highest diabetes prevalence rates in the U.S., with significant disparities by race, income, and rural residence. Despite growing recognition of sleep's role in diabetes management, sleep disturbances remain largely unaddressed in diabetes care. Cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment for chronic insomnia, yet it is underutilized in primary care clinics such as federally qualified health centers (FQHCs) that serve high-risk populations. The long-term goal of this research is to improve cardiometabolic health and reduce diabetes disparities by integrating sleep interventions into diabetes care. This pilot study aims to: (1) evaluate the impact of CBT-I on sleep and diabetes-related outcomes, and (2) assess the acceptability, feasibility, and fidelity of implementing a 6-week CBT-I program in an FQHC setting. The investigators will conduct a randomized controlled trial (RCT) with 30 FQHC patients (aged 40+) with uncontrolled T2D (HbA1c \>7%) and comorbid insomnia (Insomnia Severity Index (ISI) score ≥15). Participants will be randomly assigned to either the CBT-I intervention or usual care. Sleep (ISI scores, actigraphy) and cardiometabolic (HbA1c, fasting glucose, insulin) outcomes will be assessed at baseline and three months post-randomization. Implementation success will be evaluated using fidelity, feasibility, and acceptability measures. Findings will provide preliminary evidence for integrating CBT-I into primary care, informing larger trials to improve diabetes outcomes and reduce disparities in Louisiana.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 2 Jul 2025
- Start date
- 1 Sept 2026
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- Tulane University
- Diseases
- Type 2 diabetes
- NCT number
- NCT07062406
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 1 Sept 2026 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- having a psychiatric or medical condition that would interfere with the ability to complete study procedures
- participating in another diabetes clinical trial
Other
- diagnosed or self-reported sleep apnea
- pregnant or planning to become pregnant during the study period
- living in same household as another participant
- required to work night shifts
Who the study is looking for
- aged 40 or older
- receive primary care from participating clinic
- diagnosis of type 2 diabetes
- most recent hemoglobin A1c (HbA1c) \>7% within the past year
- Insomnia Severity Index (ISI) score ≥15
- able to speak English
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Southeast Community Health Systems Coordinator of this site? Confirm its status | Zachary | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.